AR084210A1 - PROTEINAS DE UNION AL TNF-a - Google Patents
PROTEINAS DE UNION AL TNF-aInfo
- Publication number
- AR084210A1 AR084210A1 ARP110104589A AR084210A1 AR 084210 A1 AR084210 A1 AR 084210A1 AR P110104589 A ARP110104589 A AR P110104589A AR 084210 A1 AR084210 A1 AR 084210A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- tnf
- binding proteins
- activity
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Proteínas de unión al TNF-a que incluyen anticuerpos quiméricos, con CDR injertadas y humanizados que se unen al TNF-a. Las proteínas de unión presentan una afinidad elevada por el TNF-a y neutralizan la actividad del TNF-a. Una proteína de unión puede ser un anticuerpo completo o una porción de un anticuerpo que puede unirse al TNF-a. Métodos para elaborar y usar las proteínas de unión. Las proteínas de unión al TNF-a son útiles para detectar el TNF-a y para inhibir la actividad del TNF-a, lo que puede realizarse, por ejemplo, en un sujeto humano que padece una enfermedad o un trastorno donde la actividad del TNF-a es perjudicial.Reivindicación 1: Un anticuerpo, o una porción de unión al antígeno de éste, caracterizado porque comprende SEQ ID Nº 31, SEQ ID Nº 32, SEQ ID Nº 33, SEQ ID Nº 34, SEQ ID Nº 35, SEQ ID Nº 36, SEQ ID Nº 37, SEQ ID Nº 38, SEQ ID Nº 39; SEQ ID Nº 40; SEQ ID Nº 41; SEQ ID Nº 42; SEQ ID Nº 43; SEQ ID Nº 44; SEQ ID Nº 45 o SEQ ID Nº 46.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42099910P | 2010-12-08 | 2010-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084210A1 true AR084210A1 (es) | 2013-05-02 |
Family
ID=45510463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104589 AR084210A1 (es) | 2010-12-08 | 2011-12-07 | PROTEINAS DE UNION AL TNF-a |
Country Status (24)
Country | Link |
---|---|
US (3) | US8877194B2 (es) |
EP (1) | EP2649189A4 (es) |
JP (1) | JP2014503202A (es) |
KR (1) | KR20130101123A (es) |
CN (1) | CN103459609A (es) |
AR (1) | AR084210A1 (es) |
AU (1) | AU2011338313A1 (es) |
BR (1) | BR112013014278A2 (es) |
CA (1) | CA2820671A1 (es) |
CL (1) | CL2013001625A1 (es) |
CO (1) | CO6781489A2 (es) |
CR (1) | CR20130266A (es) |
DO (1) | DOP2013000129A (es) |
GT (1) | GT201300149A (es) |
MX (1) | MX2013006428A (es) |
NZ (1) | NZ612394A (es) |
PE (1) | PE20141186A1 (es) |
RU (1) | RU2013131007A (es) |
SG (1) | SG191074A1 (es) |
TW (1) | TW201307387A (es) |
UA (1) | UA108912C2 (es) |
UY (1) | UY33786A (es) |
WO (1) | WO2012078878A2 (es) |
ZA (1) | ZA201304905B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ603045A (en) | 2010-04-07 | 2014-11-28 | Abbvie Inc | Tnf-alpha binding proteins |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
CA2853357A1 (en) * | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
AR088514A1 (es) | 2011-10-24 | 2014-06-18 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
UY34411A (es) | 2011-10-24 | 2013-05-31 | Abbvie Inc | Inmunoenlazantes dirigidos contra esclerostina |
EA035943B1 (ru) * | 2013-03-13 | 2020-09-03 | Протена Биосайенсес Лимитед | Антитело, связывающееся с тау-белком человека |
CN104004762B (zh) * | 2014-05-20 | 2016-03-30 | 南京医科大学附属南京儿童医院 | Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用 |
US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
BR112017020275A8 (pt) | 2015-03-31 | 2023-01-31 | Sorriso Pharmaceuticals Inc | Polipeptídeos |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
BR112018006953A2 (pt) * | 2015-10-05 | 2018-10-23 | Circle33 Llc | anticorpos com estabilidade melhorada para digestão intestinal |
RU2018124307A (ru) | 2015-12-04 | 2020-01-14 | Новартис Аг | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
SG11201810678WA (en) | 2016-06-02 | 2018-12-28 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
EP3534909A4 (en) * | 2016-11-02 | 2020-06-03 | Nanoproteagen | POLYMANANOPARTICLE |
GB201621907D0 (en) * | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
US20200158721A1 (en) * | 2017-01-26 | 2020-05-21 | Vital Biosciences, Inc. | Magnetic particle-based immunoassay and methods of using the same |
GB201701404D0 (en) * | 2017-01-27 | 2017-03-15 | Micropharm Ltd | Therapies for treating inflammatory disorders |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
CN107903323B (zh) * | 2017-11-15 | 2020-04-17 | 中国药科大学 | 抗hTNF-α全人源抗体及其用途 |
TWI803542B (zh) | 2017-12-01 | 2023-06-01 | 美商艾伯維有限公司 | 糖皮質激素受體激動劑及其免疫結合物 |
BR112020015016A2 (pt) * | 2018-01-26 | 2020-12-29 | Genentech, Inc. | Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas |
CN111868084B (zh) * | 2018-01-29 | 2024-03-22 | 加利福尼亚大学董事会 | 治疗tlr2介导的疾病和病症的疗法和方法 |
KR102088789B1 (ko) * | 2018-06-20 | 2020-03-13 | 인하대학교 산학협력단 | 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용 |
KR102141546B1 (ko) | 2018-12-24 | 2020-08-05 | 고려대학교 산학협력단 | 난청 예후 예측방법 및 이를 이용한 키트 |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
JP2022537780A (ja) | 2019-06-21 | 2022-08-29 | ソリッソ ファーマシューティカルズ,インク. | ポリペプチド |
KR20220064953A (ko) | 2019-06-21 | 2022-05-19 | 소리소 파마슈티컬스 인크. | 폴리펩티드 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
HU221984B1 (hu) * | 1996-02-09 | 2003-03-28 | Basf Ag | Humán TNFalfa-t kötő antitestek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
JP4754219B2 (ja) * | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
BRPI0511448A (pt) | 2004-07-06 | 2007-12-26 | Bioren Inc | anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências |
KR101539545B1 (ko) * | 2005-06-07 | 2015-07-24 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 억제하는 안정적이고 가용성인 항체 |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
WO2010006060A2 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
NZ603045A (en) | 2010-04-07 | 2014-11-28 | Abbvie Inc | Tnf-alpha binding proteins |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
CA2853357A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
-
2011
- 2011-12-07 AR ARP110104589 patent/AR084210A1/es unknown
- 2011-12-08 UY UY33786A patent/UY33786A/es not_active Application Discontinuation
- 2011-12-08 JP JP2013543343A patent/JP2014503202A/ja active Pending
- 2011-12-08 BR BR112013014278A patent/BR112013014278A2/pt not_active IP Right Cessation
- 2011-12-08 AU AU2011338313A patent/AU2011338313A1/en not_active Abandoned
- 2011-12-08 CA CA2820671A patent/CA2820671A1/en not_active Abandoned
- 2011-12-08 MX MX2013006428A patent/MX2013006428A/es not_active Application Discontinuation
- 2011-12-08 NZ NZ612394A patent/NZ612394A/en not_active IP Right Cessation
- 2011-12-08 KR KR1020137017771A patent/KR20130101123A/ko not_active Application Discontinuation
- 2011-12-08 EP EP11846172.2A patent/EP2649189A4/en not_active Withdrawn
- 2011-12-08 SG SG2013044334A patent/SG191074A1/en unknown
- 2011-12-08 UA UAA201308481A patent/UA108912C2/uk unknown
- 2011-12-08 TW TW100145384A patent/TW201307387A/zh unknown
- 2011-12-08 RU RU2013131007/10A patent/RU2013131007A/ru not_active Application Discontinuation
- 2011-12-08 US US13/314,878 patent/US8877194B2/en active Active
- 2011-12-08 WO PCT/US2011/063955 patent/WO2012078878A2/en active Application Filing
- 2011-12-08 CN CN2011800653303A patent/CN103459609A/zh active Pending
- 2011-12-08 PE PE2013001369A patent/PE20141186A1/es not_active Application Discontinuation
-
2013
- 2013-06-06 DO DO2013000129A patent/DOP2013000129A/es unknown
- 2013-06-06 CL CL2013001625A patent/CL2013001625A1/es unknown
- 2013-06-07 CR CR20130266A patent/CR20130266A/es unknown
- 2013-06-07 GT GT201300149A patent/GT201300149A/es unknown
- 2013-06-28 CO CO13154218A patent/CO6781489A2/es active IP Right Grant
- 2013-07-01 ZA ZA2013/04905A patent/ZA201304905B/en unknown
-
2014
- 2014-09-25 US US14/496,843 patent/US20150111251A1/en not_active Abandoned
-
2016
- 2016-02-15 US US15/044,059 patent/US20160272703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011338313A1 (en) | 2013-05-02 |
GT201300149A (es) | 2014-02-21 |
US20120230911A1 (en) | 2012-09-13 |
ZA201304905B (en) | 2014-12-23 |
EP2649189A1 (en) | 2013-10-16 |
US20160272703A1 (en) | 2016-09-22 |
SG191074A1 (en) | 2013-08-30 |
RU2013131007A (ru) | 2015-01-20 |
CO6781489A2 (es) | 2013-10-31 |
CL2013001625A1 (es) | 2014-02-21 |
UY33786A (es) | 2012-01-31 |
PE20141186A1 (es) | 2014-10-12 |
US8877194B2 (en) | 2014-11-04 |
BR112013014278A2 (pt) | 2017-08-01 |
EP2649189A4 (en) | 2014-05-14 |
CA2820671A1 (en) | 2012-06-14 |
UA108912C2 (uk) | 2015-06-25 |
DOP2013000129A (es) | 2013-11-15 |
KR20130101123A (ko) | 2013-09-12 |
US20150111251A1 (en) | 2015-04-23 |
NZ612394A (en) | 2015-07-31 |
TW201307387A (zh) | 2013-02-16 |
JP2014503202A (ja) | 2014-02-13 |
WO2012078878A2 (en) | 2012-06-14 |
CN103459609A (zh) | 2013-12-18 |
MX2013006428A (es) | 2014-06-11 |
CR20130266A (es) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
DOP2011000232A (es) | Proteinas de union a il-1 | |
EA201990243A1 (ru) | Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения | |
CY1120286T1 (el) | Πρωτεϊνες δεσμευσης υποδοχεα προλακτινης και χρησεις αυτων | |
UY32949A (es) | Proteínas de unión a il-1 | |
EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
IN2014MN00873A (es) | ||
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EA201592042A1 (ru) | Композиции антител против cgrp и их применение | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
CO6680693A2 (es) | Anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales en lazan especificamente a ox40 humano | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
BRPI0916945A2 (pt) | métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada. | |
EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
MX2010006767A (es) | Anticuerpos de virus de hepatitis c. | |
EA201890928A1 (ru) | Антигенсвязывающие белки, которые активируют лептиновый рецептор | |
PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
AR096445A1 (es) | Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga | |
RU2016106708A (ru) | Лекарственное средство, содержащее антитело к фосфолипазе d4 | |
EA202090278A1 (ru) | Антигенсвязывающие области против доменов фибронектина типа iii и способы их применения | |
EA202091088A1 (ru) | Антитела и химерные антигенные рецепторы, специфические для b-клеточного антигена созревания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |